Deciphex is headquartered in Dublin, Ireland with additional offices in the United States and the UK. Deciphex operates two business units, the clinical unit of Diagnexia and the pre-clinical unit of Patholytix.
Diagnexia utilizes proprietary software and workflows to enable access to a global network of pathologists in diverse specialties for secondary and primary consults.
Patholytix focuses on pre-clinical is the only digital pathology solution proven to enable GLP Peer Review of non-clinical (drug safety) studies. Through strong relationships with the leading CROs, we offer an alternative strategy for the secure onboarding and review of studies. Our superior ergonomics in study management and image review along with integrated AI, significantly improves the efficiency of our pathologist users.”
Deciphex uses digital pathology and artificial intelligence to address gaps in pathology access and efficiency in both clinical and non clinical markets. Deciphex’s Diagnexia service provides access to an international network of pathology specialists for secondary, primary and QC consults. Patholytix provides an AI driven workflow and software to improve toxopathology and tissue review in pre-clinical drug safety and development.
GDPR, CAP, CLIA (submitted), CQC (submitted)
Diagnostics; Digital Health; Healthcare; Life Sciences; Medical
Merck, Charles River Laboratories, Novartis, Janssen, NIH, Eastern Health (Canada), Mackenzie Health (Toronto, Canada)
Charles River Laboratories, Cernostics
United States, UK, EU, Canada, Emirates, Jordan, Qatar, South Africa, Mexico, Singapore, Australia, New Zealand
Tel: +353 1 582 7193